tiprankstipranks
Crinetics Pharmaceuticals (CRNX)
NASDAQ:CRNX
US Market

Crinetics Pharmaceuticals (CRNX) Ownership - Who Owns Crinetics Pharmaceuticals?

Compare
493 Followers

Crinetics Pharmaceuticals (CRNX) Ownership Overview

1.76%35.18%38.45%16.45%8.16%
38.45% Other Institutional Investors
16.45% ETFs
8.16% Public Companies and Individual Investors
The ownership structure of Crinetics Pharmaceuticals (CRNX) stock is a mix of institutional, retail, and individual investors. Approximately 90.08% of the company’s stock is owned by Institutional Investors, 1.76% is owned by Insiders, and 8.16% is owned by Public Companies and Individual Investors.
The ownership structure of Crinetics Pharmaceuticals (CRNX) stock is a mix of institutional, retail, and individual investors. Approximately 73.63% of the company’s stock is owned by Institutional Investors, 1.76% is owned by Insiders, and 16.45% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Jun 25, 2024
Dana Pizzuti
Chief Med And Dev Officer
xxxxxxxxxxxxx
$434435
Apr 02, 2024
xxxxxxxxxxxxx
$811650
Mar 26, 2024
xxxxxxxxxxxxx
$1433675
Mar 22, 2024
Dana Pizzuti
Chief Med And Dev Officer
xxxxxxxxxxxxx
$664763

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Dec 31, 2024
xxxxxxxxxxxxx
$28596344

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
8,556,852Institution9.23%301,714,602
6,141,014Institution6.62%216,532,154
5,079,425Institution5.48%179,100,526
4,111,950Institution4.43%144,987,357
4,075,098Institution4.39%143,687,955
2,284,367Institution2.46%80,546,780
2,020,841Institution2.18%71,254,854
1,754,946Institution1.89%61,879,396
1,464,650Institution1.58%51,643,559
1,252,553Institution1.35%44,165,019

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
5,079,425Institution5.48%179,100,526
2,284,367Institution2.46%80,546,780
2,020,841Institution2.18%71,254,854
1,754,946Institution1.89%61,879,396
1,464,650Institution1.58%51,643,559
1,252,553Institution1.35%44,165,019
1,080,200Institution1.16%38,087,852
1,012,628Institution1.09%35,705,263
978,722Institution1.06%34,509,738
952,423Institution1.03%33,582,435

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
2,812,517Institution3.03%143,803,994
2,357,834Institution2.54%83,137,227
2,242,579Institution2.42%114,663,064
1,419,217Institution1.53%72,564,565
1,272,775Institution1.37%65,076,986
871,077Institution0.94%30,670,621
782,549Institution0.84%27,592,678
542,460Institution0.58%19,127,140
446,880Institution0.48%15,734,645
417,298Institution0.45%21,336,447

FAQ

Who Owns Crinetics Pharmaceuticals (CRNX)?
According to the latest TipRanks data, approximately 38.45% of the company's stock is held by institutional investors, 1.76% is held by insiders, and 8.16% is held by retail investors.
    What percentage of Crinetics Pharmaceuticals (CRNX) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 38.45% of Crinetics Pharmaceuticals (CRNX) stock is held by institutional investors.
      What percentage of Crinetics Pharmaceuticals (CRNX) stock is held by retail investors?
      According to the latest TipRanks data, approximately 8.16% of Crinetics Pharmaceuticals (CRNX) stock is held by retail investors.
        Who owns the most shares of Crinetics Pharmaceuticals (CRNX)?
        Vanguard owns the most shares of Crinetics Pharmaceuticals (CRNX).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis